Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Agilent, MRM Proteomics Sign Marketing Deal

By Drug Discovery Trends Editor | September 20, 2012

Agilent Technologies Inc. announced that it has entered into a comarketing agreement with MRM Proteomics Inc., a leading provider of advanced protein quantitation, biomarker and proteomic services to the pharmaceutical, biotechnology and diagnostics industries. The agreement will allow both organizations to offer a more complete solution, including kits, hardware, and software for proteomics.

Proteomics is the study of the structure and function of proteins and how they interact within a complex biological system. Agilent’s integrated proteomics workflow provides the highest analytical performance with unprecedented plug-and-play flexibility. Interchangeable workflows simplify setups and let researchers quickly switch between different methodologies. Offering the industry’s highest sensitivity and highest throughput quantitation, the Agilent 6490 Triple Quadrupole MS/MS provides targeted MRM peptide quantitation at attomole detection levels.

“MRM Proteomics, is recognized as a pioneer and leading company in the development of mass spec based methods for protein quantification using multiple reaction monitoring,” said Steve Fischer, Agilent marketing manager, Metabolomics and Proteomics. “The agreement is a further reflection of Agilent’s continued commitment and investment in quantitative proteomics.”

MRM Proteomics specializes in the highly multiplexed absolute quantitation of proteins in complex biological samples such as blood, cerebrospinal fluid and urine through MRM-MS using isotopically labeled internal standards. MRM Proteomics’ workflows utilize minimal sample volumes (20 ul) and are capable of unparalleled specificity and sensitivity, without the need for depletion of high-abundance proteins.

“MRM Proteomics is pleased to enter into this comarketing arrangement with Agilent Technologies; our companies’ offerings are clearly complementary in the field of targeted quantitative proteomics,” said Andrew Munk, chief executive officer of MRM Proteomics. “Mass spectrometry is a rapidly growing platform driving basic proteomics research, biomarker discovery and drug development. Agilent’s status as an innovator in mass spec instrumentation combined with its extensive global network, make Agilent a great partner for MRM Proteomics.”

Date: September 13, 2012
Source: Agilent Technologies Inc.


Filed Under: Drug Discovery

 

Related Articles Read More >

Swissmedic approves first malaria treatment for infants
Korean team reports all-in-one cancer nanomedicine in pre-clinical studies
Nektar’s Phase 2b atopic dermatitis win triggers 1,746% analyst target surge, but legal tussle with ex-partner Lilly could complicate path forward
Dupixent approved to treat bullous pemphigoid
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE